Company profile: Cardea Bio
1.1 - Company Overview
Company description
- Provider of graphene-based, biology-gated transistor infrastructure and biosensing solutions, including: BPU Platform converting biological interactions into electrical signals for real-time multiomics; graphene biosensors for direct biomolecule measurement; CRISPR-Chip for gene editing efficiency; and commercial/research partnerships across healthcare, agriculture, and environmental monitoring.
Products and services
- BPU Platform: Benchtop-capable system where the Biosignal Processing Unit converts biological interactions into electrical signals for real-time multiomics data collection and analysis using biology-gated transistors
- Graphene Biosensors: Biocompatible graphene devices enabling sensitive, real-time measurement of biomolecules directly from samples without enrichment or amplification, applicable across healthcare, agriculture, and environmental monitoring
- CRISPR-Chip Technology: Chip-based technology that delivers insights into gene editing efficiency, including gRNA binding to Cas enzymes and target DNA, supporting assessment of CRISPR activity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cardea Bio
Biocoat
HQ: United States
Website
- Description: Provider of custom-engineered biomaterial coatings for medical devices, specializing in lubricious hydrophilic coatings that deliver lubricity, durability, and low particulate counts. Services include contract coating, custom polymer synthesis, and reagent fulfillment, with specialized hydrophilic solutions for neurovascular and cardiovascular devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocoat company profile →
Primerdesign
HQ: United Kingdom
Website
- Description: Provider of real-time PCR solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Primerdesign company profile →
Newport Labs
HQ: United States
Website
- Description: Provider of veterinary healthcare services and high-quality autogenous biologics for the livestock industry, applying 21st technology to a traditional autogenous approach to formulate products that pinpoint specific disease problems, supported by dedicated employees and innovative solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Newport Labs company profile →
Protea Biosciences
HQ: United States
Website
- Description: Provider of mass spectrometry standards and services, including mass spectrometry imaging via LAESI and MALDI, HGMS integrating optical microscopy and histology, and LC-MS for proteomics, metabolomics, and protein characterization, enabling direct ionization, high-resolution spatial mapping, and targeted chemical profiling across diverse sample types.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Protea Biosciences company profile →
Amaryllis Nucleics
HQ: United States
Website
- Description: Provider of proprietary RNA sequencing methods and end-to-end solutions delivering shorter turnaround from RNA to library prep and complete data analysis at a lower cost per sample compared to whole transcriptome sequencing approaches for RNASeq; Bay Area-based start-up.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amaryllis Nucleics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cardea Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cardea Bio
2.2 - Growth funds investing in similar companies to Cardea Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cardea Bio
4.2 - Public trading comparable groups for Cardea Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →